Mazdutide 9mg, targeting both glucagon and GLP-1 receptors simultaneously, achieved 12.78% weight loss versus 1.8% weight gain with placebo over 24 weeks in 80 Chinese adults with BMI ≥30. The dual-agonist approach represents a meaningful evolution beyond current single-hormone obesity medications like semaglutide, which typically deliver 10-15% weight loss. With 81.7% of participants achieving clinically meaningful ≥5% weight reduction compared to zero in the placebo group, mazdutide demonstrates robust efficacy comparable to leading obesity therapeutics. The dual mechanism theoretically offers advantages: GLP-1 activation reduces appetite and slows gastric emptying, while glucagon receptor activation may enhance energy expenditure and prevent metabolic adaptation. However, gastrointestinal side effects were substantial—50% experienced nausea versus none with placebo, suggesting tolerability challenges that could limit real-world adherence. The 24-week timeframe, while standard for obesity drug trials, leaves questions about long-term sustainability and safety. Most importantly, this small phase 2 study in a specific population requires larger, diverse trials before drawing broader conclusions about mazdutide's therapeutic potential in global obesity management.